Digital Desk, New Delhi. Bahrain’s National Health Regulatory Authority (NHRA) on Friday approved India’s first indigenous vaccine against Corona, Covaxin, for emergency use. Covaxin, manufactured by Hyderabad-based pharma major Bharat Biotech, will be available in Bahrain for people aged 18 and above after approval.
People traveling from India to Bahrain with a WHO-approved vaccine certificate issued in India will be exempted from the 10-day mandatory quarantine and a pre-arrival negative RT-PCR report. In a statement, the NHRA said the decision follows a careful evaluation of the data provided by the Clinical Trials Committee of the Biotech Authority of India and the Immunization Committee of the Ministry of Health of Bahrain. More than 26,000 people participated in clinical trials of the vaccine, of which the two-dose regimen is 77.8 percent effective against coronavirus and 93.4 percent effective against severe cases of the virus.
The NHRA further said, the safety data indicated a low incidence of adverse effects. Recently, the World Health Organization provided an emergency use list to countries enabling Covaxin to accelerate their regulatory approval for the import and administration of supplements.